Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857116 | 0.91 | DPP4 (0.37) | HSD11B1DPP4 | |
| SCHEMBL27510109 | 0.86 | EPHX1 (0.39) | HSD11B1EPHX1DPP4GAA | |
| SCHEMBL27623896 | 0.85 | DPP4 (0.36) | HSD11B1EPHX1DPP4GAABTK | |
| SCHEMBL13668663 | 0.84 | MC4R (0.37) | HSD11B1EPHX1DPP4GAA | |
| SCHEMBL16265413 | 0.84 | EPHX1 (0.35) | HSD11B1EPHX1DPP4GAA | |
| SCHEMBL24577516 | 0.83 | DPP4 (0.37) | HSD11B1EPHX1DPP4BTK | |
| SCHEMBL13769592 | 0.83 | EPHX1 (0.37) | HSD11B1EPHX1DPP4GAAL3MBTL1 | |
| SCHEMBL5965337 | 0.82 | — | — | |
| SCHEMBL923554 | 0.82 | EPHX1 (0.39) | HSD11B1EPHX1DPP4GAAMEN1 | |
| SCHEMBL13494079 | 0.82 | ADH1A (0.41) | HSD11B1EPHX1GAAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3427738-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10874673-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-29 | — | — | US | disclosed |
| CN-104922128-B | Inhibitors of influenza virus replication | 沃泰克斯药物股份有限公司 | 2019-12-20 | — | — | CN | disclosed |
| CN-110540538-A | Inhibitors of influenza virus replication | VERTEX PHARMA | 2019-12-06 | — | — | CN | disclosed |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| EP-3427738-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10039762-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3141252-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180078553-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-22 | — | — | US | disclosed |
| US-9808459-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-13 | — | — | US | disclosed |
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2442809-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078553-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | HSD11B1 1023/4885EPHX1 3137/4885DPP4 874/4885 |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | HSD11B1 1023/4885EPHX1 3137/4885DPP4 874/4885 |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | HSD11B1 1023/4885EPHX1 3137/4885DPP4 874/4885 |
| US-10874673-B2 | Inhibitors of influenza viruses replication | ACE, IRF3, ACE2 | HSD11B1 1023/4885EPHX1 3137/4885DPP4 874/4885 |
| US-10039762-B2 | Inhibitors of influenza viruses replication | ACE, IRF3, ACE2 | HSD11B1 1023/4885EPHX1 3137/4885DPP4 874/4885 |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | HSD11B1 1023/4885EPHX1 3137/4885DPP4 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.